Narcolepsy treatment in Sweden: An observational study

Area of Science:

• Pharmacology
• Health Services Research
• Epidemiology

Background:

• Narcolepsy diagnosis and treatment patterns require detailed understanding for effective healthcare management.
• Previous research has not comprehensively analyzed pharmacological treatments and healthcare utilization in the Swedish narcolepsy population.

Purpose of the Study:

• To describe pharmacological treatments (2005-2017) and healthcare utilization (1997-2016) for narcolepsy patients in Sweden.
• To establish a foundation for future organizational and economic analyses of narcolepsy care.

Main Methods:

• Inclusion of all ages with narcolepsy from the Swedish National Patient Registry in specialist care.
• Data on narcolepsy treatments obtained from The Swedish Prescribed Drug Register.

Main Results:

• 2508 narcolepsy patients identified; 47.9% received modafinil, 33.8% methylphenidate, and 26.2% amphetamine.
• Women were more likely than men to use modafinil, methylphenidate, amphetamine, and antidepressants.
• Patients on sodium oxybate exhibited increased outpatient visits pre- and during treatment compared to other narcolepsy patients.

Conclusions:

• The study provides crucial data on narcolepsy pharmaceutical treatments and healthcare utilization in Sweden.
• Increased outpatient visits for sodium oxybate users may indicate disease severity or close monitoring for side effects.
• Findings can inform future healthcare cost estimations and resource allocation for narcolepsy management.